{"groups":[{"description":"Patients receive oral thalidomide daily and oral prednisone every other day for 4 years in the absence of disease progression or unacceptable toxicity.\n\nprednisone: Given orally\n\nthalidomide: Given orally","id":"FG000","title":"Prednisone"},{"description":"Patients undergo observation.","id":"FG001","title":"Observation"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}],"type":"No receive treatment/lost to follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"166"},{"groupId":"FG001","numSubjects":"166"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"165"},{"groupId":"FG001","numSubjects":"163"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}